Kensey Nash's carotid device:
This article was originally published in Clinica
Kensey Nash is entering the carotid market, after having gained European approval to use its embolic protection system - TriActiv ProGuard - in carotid stenting procedures. The product, which was launched in Europe last year for use in saphenous vein graft procedures, is designed for use in branched anatomy, such as those of the carotid arteries. It prevents material or debris, dislodged during stent procedures, from embolising and causing adverse events such as a heart attack or stroke. The Exton, Pennsylvania company estimates that around 50,000 carotid artery stenting procedures are currently performed worldwide each year, a small percentage of the over 500,000 people who suffer from carotid artery disease. A carotid clinical trial in the US is underway to support FDA clearance of the product.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.